A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended
Phase 2 dose (RP2D), safety and efficacy of TAK-659 in combination with nivolumab in
participants with advanced solid tumors.